

If you have synovial sarcoma,

Ask your doctor about biomarker testing for TECELRA today!

TECELRA is the first and only one-time treatment for certain people as young as 12 years old with advanced synovial sarcoma when other kinds of treatments do not work. Two biomarker tests can help your medical team determine if TECELRA is right for you.

Use this guide to help start a conversation about biomarker testing with your medical team. **Additional information is included to the right of each question to help you understand how these discussion points can make a meaningful difference in your treatment journey.** Consider asking your medical team the following questions:

QUESTIONS TO ASK

HOW THIS INFORMATION CAN HELP



Am I eligible for treatment with TECELRA?



There are several requirements to determine if TECELRA may be right for you. These include the presence of certain HLA and MAGE-A4 biomarkers.



I have had many tests run already. Have I been tested for HLA and MAGE-A4 biomarkers?



You likely have already had several tests performed to help your medical team understand your disease and diagnosis. To determine whether TECELRA may be an option for you, biomarker testing must show both an eligible HLA type and MAGE-A4 expression in your tumor. Your doctor can order tests to check for both biomarkers.

Ask your doctor about your testing history.



Do I have to have another biopsy?



There are a lot of factors that go into answering this question. Those may include how your initial samples were prepared and/or stored. Your medical team will need to look at these factors before they can answer this question.

HLA=human leukocyte antigen; MAGE=melanoma-associated antigen.

What is TECELRA?

TECELRA® (afamitresgene autoleucel) is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you.

SELECT IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 2 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

QUESTIONS TO ASK



When should I be tested for biomarkers?



Knowing your biomarker status early can help you and your healthcare team make informed treatment decisions today and prepare for future options. Even if your synovial sarcoma is not advanced, biomarker testing early in your journey may help avoid delays if treatment decisions need to be made later. If you're not sure whether you've already been tested, ask your doctor about your biomarker status or whether testing can be scheduled.



If my samples previously tested negative for eligibility for TECELRA, should I get tested again?



Depending on why your samples tested negative, your medical team may recommend retesting to see if TECELRA is right for you.



If I'm positive for both biomarkers or just one, what happens next?



It takes about a week to receive the biomarker test results. Once received, your medical team will give you a call to discuss next steps. In order to be eligible for treatment with TECELRA, you need to be positive for MAGE-A4 and have a certain HLA type.



If I qualify for treatment with TECELRA, what happens next?



In order to be eligible for TECELRA, you need to be positive for MAGE-A4 and have a certain HLA type. It takes about 1 week to receive the biomarker results. Once received, your medical team will inform you of your biomarker status and any other requirements for eligibility.



Ask your doctor about HLA and MAGE-A4 biomarker testing for TECELRA today!

For personalized assistance, contact your Cell Therapy Navigator (CTN) at 1-855-246-9232, Monday through Friday 8:00 AM to 8:00 PM ET, or email mycellassist@usworldmeds.com.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, fatigue, musculoskeletal pain, infection, fever (100.4°F/38°C or higher), constipation, vomiting, headache, diarrhea, cough, fast heart rate, swelling, shortness of breath, rash, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, decreased red blood cell count, and decreased platelet count.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to US WorldMeds at 1-855-246-9232. Please see additional Important Safety Information, including Important Warning, throughout, as well as [Medication Guide](#).